The co-blockade of CTLA-4 and LAG-3 or PD-1 and LAG-3 showed better therapeutic efficacy through increased CD8+T cells with/without the reduction of Tregs in the tumor, compared to single CTLA-4 or PD-1 targeting (114). The gene discussed is LAG3; the disease is neoplasm.